Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
Moderna Japan said on October 14 that it has launched its Spikevax COVID-19 vaccine adapted to the LP.8.1 lineage of the Omicron JN.1 variant for children aged six months to 11 years. The pediatric formulation, officially named Spikevax Intramuscular Injection…
To read the full story
Related Article
- Moderna Rolls Out LP.8.1-Tailored Spikevax in Japan
September 24, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- Japan Approves Updated Spikevax for LP.8.1 Omicron Strain
August 6, 2025
- Moderna Japan Files Updated COVID Shot for Age 11 and Under
June 30, 2025
- Moderna Files Updated Spikevax for LP.8.1 Strain in Japan
June 9, 2025
- Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
May 30, 2025
BUSINESS
- Incyte Looks to More Than Double International Business by 2030: CEO
March 18, 2026
- Stella Pharma Files Steboronine for Recurrent Meningioma
March 18, 2026
- SymBio Enrolls First Patient in US for PIII BCV Trial in Adenovirus Infection
March 18, 2026
- Oral Flu Drugs Prescribed to 2.46 Million in February as Cases Surge Again: Intage
March 17, 2026
- ADDP, Proteros Tie Up to Expand Drug Discovery Support
March 17, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…